Related Experiment Videos
In vitro dissolution of piroxicam capsules
1Department of Pharmacy, General Infirmary, Leeds, Yorkshire, U.K.
Journal of Clinical Pharmacy and Therapeutics
|February 1, 1994
Summary
Piroxicam capsules from various UK suppliers met dissolution standards. All tested brands showed satisfactory drug release, with over 75% dissolving within 45 minutes in simulated gastric fluid.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery
- Pharmacokinetics
Background:
- Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation.
- Ensuring consistent in vitro drug release from generic formulations is crucial for therapeutic efficacy.
- Variability in dissolution rates can impact patient outcomes and regulatory compliance.
Purpose of the Study:
- To evaluate the in vitro dissolution performance of piroxicam capsules from different United Kingdom suppliers.
- To compare the dissolution profiles of 10-mg and 20-mg piroxicam capsules.
- To assess compliance with established dissolution specifications.
Main Methods:
- In vitro dissolution testing was performed using the rotating basket apparatus.
- Simulated gastric fluid was used as the dissolution medium.
- Seven different brands of piroxicam capsules were analyzed.
Main Results:
- All seven tested brands of piroxicam capsules demonstrated satisfactory dissolution.
- Each brand achieved at least 75% piroxicam dissolution within the 45-minute timeframe.
- No significant differences in dissolution were noted that would raise concerns about product quality.
Conclusions:
- The tested piroxicam capsules from various UK suppliers meet in vitro dissolution requirements.
- The findings suggest consistent drug release performance across different brands.
- This supports the interchangeability of these piroxicam formulations.